Skip to main content

Table 1 Parameter definitions and values associated with the different WHO regions

From: High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

Parameters WHO regions
Notation Definition African American Eastern Mediter. European South-East Asia Western Pacific Global
Inca Incidence (new cases/100,000/year) 275 (239–314) 27 (25–29) 116 (86–149) 36 (33–38) 246 (167–339) 86 (78–94) 142 (119–166)
aa rate of MDR/RR-TB among new TB-cases (%) 3 (1.2-4.9) 2.9 (1.6-4.2) 4.1 (3–5.1) 16 (11–20) 2.6 (2.3-3) 5.1 (3–7.2) 3.9 (2.7-5.1)
bb drug sensitivity testing coverage in new TB-cases (%) 21 29 2 44 5.1 8.8 24
cb treatment success rates for new DS-TB cases (%) 81 76 91 76 79 92 83
db treatment success rates for MDR/RR-TB cases (%) 54 55 68 52 49 57 52
ec treatment success rate for MDR/RR-TB treated with first-line regimen (%) 0-20 0-20 0-20 0-20 0-20 0-20 0-20
fc risk of drug-resistance amplification for a DS-TB patient failing therapy (%) 10-20 10-20 10-20 10-20 10-20 10-20 10-20
hb proportion of detected MDR/RR-TB cases that start on second-line regimen (%) 68.64 75.16 82.5 100 90.81 76.14 94.6
mb death proportion during treatment for DS-TB and MDR/RR-TB patients (%) 5.76 6.95 1.84 7.85 3.52 2.05 3.84
kb death proportion during treatment for MDR/RR-TB (%) 20.58 8.22 16.03 15.61 20.59 9.51 16.84
  1. a95% Confidence Intervals as reported in the WHO TB report 2016
  2. bConfidence Intervals not available
  3. cEstimated from literature